Homolak, J., Kodvanj, I. & Trkulja, V. (2021). An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19. Clinical Drug Investigation, 41. (3), 287-289. doi: 10.1007/s40261-021-01007-8

Homolak, Jan, et al. "An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19." Clinical Drug Investigation, vol. 41, no. 3, 2021, pp. 287-289. https://doi.org/10.1007/s40261-021-01007-8

Homolak, Jan, Ivan Kodvanj and Vladimir Trkulja. "An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19." Clinical Drug Investigation 41, no. 3 (2021): 287-289. https://doi.org/10.1007/s40261-021-01007-8

Homolak, J., Kodvanj, I. and Trkulja, V. (2021) 'An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19', Clinical Drug Investigation, 41(3), pp. 287-289. doi: 10.1007/s40261-021-01007-8

Homolak J, Kodvanj I, Trkulja V. An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19. Clinical Drug Investigation [Internet]. 2021 March [cited 2024 November 23];41(3):287-289. doi: 10.1007/s40261-021-01007-8

J. Homolak, I. Kodvanj and V. Trkulja, "An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19", Clinical Drug Investigation, vol. 41, no. 3, pp. 287-289, March 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:944205. [Accessed: 23 November 2024]